Laboratory tests showed elevated eosinophils, lymphocytes, and immunoglobulins, along with thrombocytopenia. Imaging revealed focal low-density areas in the lungs and erythematous lesions on the ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

Preliminary Phase 2 data presented in November at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting showed that a combination of AU-007 and low-dose, subcutaneous aldesleukin is ...

Continuing our series, Dr Andrew Whittamore debunks some common myths about asthma – and explains some less well-known facts ...

Immunodeficiency disorders linked to cytoskeleton defects are rare and complex, often presenting with diverse clinical features. This case report highlights a patient with recurrent eosinophilia and a ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...

Chronic lower respiratory diseases, namely, asthma and chronic obstructive pulmonary disease , are the fifth-leading cause of ...

A single daily preventer dose of inhaled corticosteroid (beclomethasone), taken at mid-afternoon, may be the best timing for ...

Mid-afternoon dosing of inhaled corticosteroids may be the most effective timing for controlling asthma symptoms and ...

An afternoon dose also yielded significantly better overnight (10 p.m. to 4 a.m.) suppression in blood eosinophil counts as a marker of airway inflammation compared with the other two groups, although ...